Regulus Therapeutics Income Statement

Financials in millions HKD. Fiscal year is January - December.

Millions HKD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023	FY 2022
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022
Revenue	36.46	49.12	37.77
Revenue Growth (YoY)	-25.77%	30.04%	-
Cost of Revenue	22.08	25.24	22.22
Gross Profit	14.38	23.88	15.56
Selling, General & Admin	31.86	15.32	15.63
Other Operating Expenses	-1.67	-0.01	-0.93
Operating Expenses	30.73	16.3	15.89
Operating Income	-16.35	7.58	-0.33
Interest Expense	-2.02	-0.55	-0.69
Interest & Investment Income	0.29	0.05	0
Currency Exchange Gain (Loss)	-	-	0
EBT Excluding Unusual Items	-18.07	7.08	-1.02
Other Unusual Items	-	-	0.92
Pretax Income	-18.07	7.08	-0.1
Net Income	-18.07	7.08	-0.1
Net Income to Common	-18.07	7.08	-0.1
Shares Outstanding (Basic)	13	13	13
Shares Outstanding (Diluted)	13	13	13
Shares Change (YoY)	5.43%	-	-
EPS (Basic)	-1.37	0.57	-0.01
EPS (Diluted)	-1.37	0.57	-0.01
Free Cash Flow	-12.9	6.83	5.01
Free Cash Flow Per Share	-0.98	0.55	0.40
Gross Margin	39.44%	48.62%	41.18%
Operating Margin	-44.83%	15.43%	-0.88%
Profit Margin	-49.57%	14.41%	-0.26%
Free Cash Flow Margin	-35.38%	13.89%	13.25%
EBITDA	-11.9	12.6	4.71
EBITDA Margin	-32.64%	25.65%	12.48%
D&A For EBITDA	4.44	5.02	5.05
EBIT	-16.35	7.58	-0.33
EBIT Margin	-44.83%	15.43%	-0.88%

Updated Oct 18, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q